-The expression of cortistatin in human and mouse livers inversely
correlates with the severity of fibrosis and cirrhosis.
-Treatment with cortistatin ameliorates fibrosis progression and
activation of myofibroblasts in two models of hepatotoxic and
cholestatic liver injury.
-Deficiency in cortistatin significantly exacerbates fibrogenic
responses, hepatic damage and mortality.
-We identify to cortistatin as an endogenous molecular break for the
activation of hepatic stellate cells and fibroblasts and for the
differentiation of myofibroblasts in liver.